DFX Intelligence

Data Factory

Private equityFirmprivate credit · probableupper middle market

Healthcare Royalty Management, LLC

Private Equity

Stamford, CT

HealthCare Royalty Partners is an investment firm that purchases royalties and uses debt-like structures to invest in commercial stage assets.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:513e4600-5ee3-4c90-86d4-d909b5bb721a

Data as of Sep 13, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 21, 2026, 9:22 AM UTC and rebuilt at most every 15 minutes.

Relationships: 107
Dated events: 35
On other graphs: 2
Observed: Sep 13, 2026 to Sep 13, 2026
34 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Independent Sponsorsidentity

Healthcare Royalty Management, LLC

Capital provider to sponsors · shared crd

RIA / Wealth Managementidentity

HEALTHCARE ROYALTY MANAGEMENT, LLC

Registered adviser · shared crd

Private Creditcandidate

Healthcare Royalty Management, LLC

Credit provider · carried

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 15
PE funds: 15
Vintages: 2017 to 2024
PE GAV, 2024 filing: $6.0Bgross asset value on Form ADV; never dry powder
Regulatory AUM: $3.5B
Investments: 71
Active investments: 0
Size band: UPPER MIDDLE MARKETderivedproxy: $6.03bn Private Equity Fund GAV on the Form ADV filed 2024-03-27
Stated control: majority,minority
Latest ADV filing: Mar 27, 2024
Employees (ADV): 23
Website: hcroyalty.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV
HCR Potomac Fund II, L.P.	2024	Unknown	Private Equity Fund	n/a	$100M
HCR Stafford Fund II, L.P.	2024	Unknown	Private Equity Fund	n/a	$150M
Hcrx Investments Holdco, L.P.	2023	Early deployment	Private Equity Fund	n/a	$1.3B
Hcrx Holdings L.P.	2023	Early deployment	Private Equity Fund	n/a	$1.3B
Hcrx Intermediate Holdco, L.P.	2023	Early deployment	Private Equity Fund	n/a	$1.3B
HCR Canary Fund, L.P.	2021	Unknown	Private Equity Fund	n/a	$45.8M
HCR Potomac Fund, L.P.	2020	Wound down	Private Equity Fund	n/a	$256M
Healthcare Royalty Partners IV, L.P.	2019	Harvest	Private Equity Fund	n/a	$1.1B
HCR Molag Fund, L.P.	2018	Mature	Private Equity Fund	n/a	$172M
HCR Stafford Fund, L.P.	2017	Wound down	Private Equity Fund	n/a	$409M
HCR H.O.P. Fund, L.P.	2017	Harvest	Private Equity Fund	n/a	$9.5M
Healthcare Royalty Partners III, L.P.	n/a	Harvest	Private Equity Fund	n/a	$574M
Healthcare Royalty Partners, L.P.	n/a	Harvest	Private Equity Fund	n/a	$24.5M
Healthcare Royalty Partners II, L.P.	n/a	Wound down	Private Equity Fund	n/a	$96.4M
Hcrp Overflow Fund, L.P.	n/a	Wound down	Private Equity Fund	n/a	$282M

Investments

Company	State	Role	Control	Invested	Exited	Status
UTEBZI (tebipenem HBr)	n/a	unknown	unknown	n/a	n/a	unknown
Various	n/a	unknown	unknown	n/a	n/a	unknown
Ad109	n/a	unknown	unknown	n/a	n/a	unknown
NEXLETOL®, NEXLIZET®, ENBUMYST®	n/a	unknown	unknown	n/a	n/a	unknown
JNJ-1900 (NBTXR3)	n/a	unknown	unknown	n/a	n/a	unknown
Beyonttra	n/a	unknown	unknown	n/a	n/a	unknown
YUTREPIA™, Treprostinil	n/a	unknown	unknown	n/a	n/a	unknown
IQIRVO®	n/a	unknown	unknown	n/a	n/a	unknown
BRIUMVI®	n/a	unknown	unknown	n/a	n/a	unknown
Genotropin / Ngenla	n/a	unknown	unknown	n/a	n/a	unknown
Xpoviotm	n/a	unknown	unknown	n/a	n/a	unknown
Rare Disease Assets	n/a	unknown	unknown	n/a	n/a	unknown
TLX250-CDx	n/a	unknown	unknown	n/a	n/a	unknown
Korsuva/Kapruvia	n/a	unknown	unknown	n/a	n/a	unknown
Bexacat	n/a	unknown	unknown	n/a	n/a	unknown
RELISTOR®	n/a	unknown	unknown	n/a	n/a	unknown
Hemgenix®	n/a	unknown	unknown	n/a	n/a	unknown
Ebvallo	n/a	unknown	unknown	n/a	n/a	unknown
XIPERE, ARVN001, RGX-314, AU-011	n/a	unknown	unknown	n/a	n/a	unknown
Tenapanor	n/a	unknown	unknown	n/a	n/a	unknown
Imcivree	n/a	unknown	unknown	n/a	n/a	unknown
Tebipenem HBr	n/a	unknown	unknown	n/a	n/a	unknown
Zynlontatm	n/a	unknown	unknown	n/a	n/a	unknown
Ruxience	n/a	unknown	unknown	n/a	n/a	unknown
Vafseo	n/a	unknown	unknown	n/a	n/a	unknown
ZOLGENSMA®	n/a	unknown	unknown	n/a	n/a	unknown
ADYNOVATE®, MOVANTIK®	n/a	unknown	unknown	n/a	n/a	unknown
MYCAPSSA®	n/a	unknown	unknown	n/a	n/a	unknown
Movantik®, Talicia®, Aemcolo®	n/a	unknown	unknown	n/a	n/a	unknown
Trelegy Ellipta	n/a	unknown	unknown	n/a	n/a	unknown

Relationships

showing 80 of 107

Firm member (1)

→ Healthcare RoyaltyFirmAnchor adviser
factDFX's own graph

Employs (7)

→ Andrew PalmerPersonInterview with Dr. Robert Langer, HCRx Senior Advisor
factThe subject's own site
→ Warren H CooperPersonMB, BS, BSc, MFPMChief Medical Officer
factThe subject's own site
→ Timothy Richard Morgan BryantPersonGeneral Counsel
May 1, 2022 to presentfactForm ADV
→ Thomas Kreuz ConnerPersonChief Accounting Officer
Apr 1, 1992 to presentfactForm ADV
→ Spencer Harris SchneiderPersonChief Compliance Officer And Chief Patent Counsel
Feb 1, 2012 to presentfactForm ADV
→ Christopher Andrew WhitePersonPresident And Chief Financial Officer
Dec 1, 2014 to presentfactForm ADV
→ Clarke Brannen FutchPersonMember
Nov 1, 2007 to presentfactForm ADV

Invested in (71)

→ Genotropin / NgenlaCompanyunknown
factThe subject's own site
→ Bayer AGCompanyunknown
factThe subject's own site
→ IPSENCompanyunknown
factThe subject's own site
→ CSL Vifor/Maruishi PharmaCompanyunknown
factThe subject's own site
→ ELANCOCompanyunknown
factThe subject's own site
→ BAUSCH HEALTH COMPANIESCompanyunknown
factThe subject's own site
→ SANOFICompanyunknown
factThe subject's own site
→ CSL LimitedCompanyunknown
factThe subject's own site
→ Bausch + Lomb, RegenexBio, etc.Companyunknown
factThe subject's own site
→ Bausch + LombCompanyunknown
factThe subject's own site
→ PfizerCompanyunknown
factThe subject's own site
→ Novartis AGCompanyunknown
factThe subject's own site
→ RedHill BiopharmaCompanyunknown
factThe subject's own site
→ Takeda Pharmaceutical Co. Ltd.Companyunknown
factThe subject's own site
→ UCB SACompanyunknown
factThe subject's own site
→ GLAXOSMITHKLINE PLCCompanyunknown
factThe subject's own site
→ AlmirallCompanyunknown
factThe subject's own site
→ Verastem OncologyCompanyunknown
factThe subject's own site
→ EA Pharma Co., LtdCompanyunknown
factThe subject's own site
→ Biogen, Inc.Companyunknown
factThe subject's own site
→ Roche/GenentechCompanyunknown
factThe subject's own site
→ SalixCompanyunknown
factThe subject's own site
→ Inavir®Companyunknown
factThe subject's own site
→ United TherapeuticsCompanyunknown
factThe subject's own site
→ Astellas EuropeCompanyunknown
factThe subject's own site
→ Merck SeronoCompanyunknown
factThe subject's own site
→ Galderma/AllerganCompanyunknown
factThe subject's own site
→ ViiV/GSKCompanyunknown
factThe subject's own site
→ UTEBZI (tebipenem HBr)Companyunknown
factThe subject's own site
→ VariousCompanyunknown
factThe subject's own site
and 41 more

Manages (1)

→ HCR H.O.P. Fund, L.P.FundPrivate Equity Fund
Mar 24, 2017 to presentfactForm ADV

Dated events

19 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Apr 2, 2026
Firm news
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
The subject's own siteobserved 7 days ago
Occurred
Mar 3, 2026
Firm news
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
The subject's own siteobserved 7 days ago
Occurred
Jul 30, 2025
Firm news
KKR Announces Strategic Acquisition of HealthCare Royalty Partners, Expanding the Firm’s Health Care Franchise and Enhancing its Life Sciences Strategy
The subject's own siteobserved 7 days ago
Occurred
Mar 27, 2024
Person left
John a Urquhart (Senior Managing Director) no longer on Schedule A of Healthcare Royalty Management, LLC
Form ADVobserved 7 days ago
Occurred
Mar 27, 2024
Person left
Warren H Cooper (Senior Managing Director) no longer on Schedule A of Healthcare Royalty Management, LLC
Form ADVobserved 7 days ago
Occurred
Mar 31, 2023
Person left
Andrew Thomas Reardon (Chief Legal Officer) no longer on Schedule A of Healthcare Royalty Management, LLC
Form ADVobserved 7 days ago
Occurred
Mar 31, 2023
Person left
Gregory Bailey Brown (Vice Chairman) no longer on Schedule A of Healthcare Royalty Management, LLC
Form ADVobserved 7 days ago
Occurred
Mar 31, 2023
Person left
Paul Hadden (Senior Managing Director) no longer on Schedule A of Healthcare Royalty Management, LLC
Form ADVobserved 7 days ago
Occurred
May 1, 2022
Person joined
Timothy Richard Morgan Bryant joined Schedule A of Healthcare Royalty Management, LLC as General Counsel
Form ADVobserved 7 days ago
Occurred
Mar 27, 2018
Person left
Todd Christopher Davis (Managing Partner) no longer on Schedule A of Healthcare Royalty Management, LLC
Form ADVobserved 7 days ago
Occurred
Mar 27, 2018
Person left
Matthew Quinn Reber (Managing Director) no longer on Schedule A of Healthcare Royalty Management, LLC
Form ADVobserved 7 days ago
Occurred
Jan 1, 2018
Person joined
John a Urquhart joined Schedule A of Healthcare Royalty Management, LLC as Partner
Form ADVobserved 7 days ago
Occurred
Jan 1, 2017
Person joined
Warren H Cooper joined Schedule A of Healthcare Royalty Management, LLC as Chief Medical Officer
Form ADVobserved 7 days ago
Occurred
Dec 1, 2014
Person joined
Christopher Andrew White joined Schedule A of Healthcare Royalty Management, LLC as Chief Operating Officer
Form ADVobserved 7 days ago
Occurred
Mar 17, 2014
Adviser first adv filing
Healthcare Royalty Management, LLC first filed Form ADV in the extract (IA)
Form ADVobserved 7 days ago
Occurred
Apr 1, 2007
Person joined
Paul Hadden joined Schedule A of Healthcare Royalty Management, LLC as Managing Director
Form ADVobserved 7 days ago

Show 19 bookkeeping events

Occurred
Mar 27, 2024
HCR Stafford Fund II, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $150,000,000
Occurred
Mar 27, 2024
Fund 805-3209438806 no longer reported on Form ADV by Healthcare Royalty Management, LLC
Occurred
Mar 27, 2024
Fund 805-4278181028 no longer reported on Form ADV by Healthcare Royalty Management, LLC
Occurred
Mar 27, 2024
HCR Potomac Fund II, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $100,000,000
Occurred
Mar 31, 2023
Fund 805-3625748903 no longer reported on Form ADV by Healthcare Royalty Management, LLC
Occurred
Mar 31, 2023
Hcrx Intermediate Holdco, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $901,155,562
Occurred
Mar 31, 2023
Hcrx Holdings L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $901,155,562
Occurred
Mar 31, 2023
Hcrx Investments Holdco, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $901,155,562
Occurred
Mar 31, 2023
Fund 805-8299503532 no longer reported on Form ADV by Healthcare Royalty Management, LLC
Occurred
Mar 30, 2021
HCR Canary Fund, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $50,714,676
Occurred
Mar 27, 2020
HCR Potomac Fund, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $176,767,677
Occurred
Mar 26, 2019
Healthcare Royalty Partners IV, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $549,853,535
Occurred
Mar 27, 2018
HCR Molag Fund, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $146,342,008
Occurred
Mar 24, 2017
HCR H.O.P. Fund, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $213,724,896
Occurred
Mar 24, 2017
HCR Stafford Fund, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $230,483,658
Occurred
Mar 17, 2014
Healthcare Royalty Partners, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $235,947,347
Occurred
Mar 17, 2014
Healthcare Royalty Partners III, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $50,991,909
Occurred
Mar 17, 2014
Healthcare Royalty Partners II, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $959,178,754
Occurred
Mar 17, 2014
Hcrp Overflow Fund, L.P. first reported on Form ADV by Healthcare Royalty Management, LLC (Private Equity Fund), GAV $155,280,012

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Warren H Cooper
MB, BS, BSc, MFPMChief Medical Officer · Revealable: 1 professional profile (firm website)

Also named here, with no published line of their own (reach them through the firm): Andrew Palmer (Interview with Dr. Robert Langer, HCRx Senior Advisor), Timothy Richard Morgan Bryant (General Counsel), Thomas Kreuz Conner (Chief Accounting Officer), Spencer Harris Schneider (Chief Compliance Officer And Chief Patent Counsel), Christopher Andrew White (President And Chief Financial Officer), Clarke Brannen Futch (Member).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:513e4600-5ee3-4c90-86d4-d909b5bb721a
First observed: Sep 13, 2026
Last observed: Sep 13, 2026 7 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Healthcare Royalty Management, LLC

Private Equity

Stamford, CT

HealthCare Royalty Partners is an investment firm that purchases royalties and uses debt-like structures to invest in commercial stage assets.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:513e4600-5ee3-4c90-86d4-d909b5bb721a

Data as of Sep 13, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 21, 2026, 9:22 AM UTC and rebuilt at most every 15 minutes.